Division of Nephrology, Department of Internal Medicine, University of Missouri-Columbia School of Medicine, 5 Hospital Drive, Columbia, MO, 65212, USA.
Curr Hypertens Rep. 2014 Mar;16(3):417. doi: 10.1007/s11906-013-0417-5.
Incretin-based therapies are now well established for diabetes management and are among the frontline agents for control of hyperglycemia. In addition to their antihyperglycemic effects, evidence is emerging on the role of these agents on blood pressure regulation, cardioprotective and renoprotective properties. Because of the pleiotropic nature of these affects, these agents could offer significant benefits with regards to the cardiorenal metabolic complications that are part of the diabetes and obesity epidemic in the United States and worldwide. We review the various known mechanisms or pathways by which incretin based therapy exerts its regulation of blood pressure with emphasis on novel mechanisms such as inflammation/immunomodulation and oxidative stress.
基于肠促胰岛素的治疗方法现已广泛用于糖尿病的管理，是控制高血糖的一线药物。除了具有降血糖作用外，这些药物在调节血压、心脏保护和肾脏保护方面的作用也有证据。由于这些作用具有多效性，这些药物可能会对美国和全球糖尿病和肥胖流行所带来的心脏和肾脏代谢并发症产生重大影响。我们回顾了肠促胰岛素治疗调节血压的各种已知机制或途径，重点介绍了炎症/免疫调节和氧化应激等新机制。
